Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B6ZM0X53 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 11.75 1,544 08:00:00
Bid Price Offer Price High Price Low Price Open Price
11.50 12.00 11.75 11.75 11.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 11.03 -18.86 -21.30 10
Last Trade Time Trade Type Trade Size Trade Price Currency
12:58:11 O 253 11.50 GBX

Hvivo (HVO) Latest News (2)

Hvivo News

Date Time Source Headline
11/12/201907:00UKREGhVIVO plc Form 8 (OPD)
10/12/201914:34UKREGForm 8.3 - Hvivo Plc
10/12/201913:33UKREGInvesco Ltd.: Form 8.3 - Hvivo Plc
10/12/201912:58UKREGNumis Securities Limited Form 8.5 (EPT/RI) - hVIVO PLC
10/12/201907:01UKREGhVIVO plc Rule 2.9 Announcement
09/12/201913:10UKREGhVIVO plc Total Voting Rights
09/12/201911:23ALNCAIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up
09/12/201907:11ALNCFAlliance News Flash Headline
09/12/201907:00UKREGhVIVO plc Recommended Merger of hVIVO with Open Orphan
11/11/201914:19UKREGhVIVO plc Exercise of Share Options
More Hvivo News
Hvivo Takeover Rumours

Hvivo (HVO) Discussions and Chat

Hvivo Forums and Chat

Date Time Title Posts
10/12/201913:52hVIVO plc2,726

Add a New Thread

Hvivo (HVO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hvivo trades in real-time

Hvivo (HVO) Top Chat Posts

Hvivo Daily Update: Hvivo Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 11.75p.
Hvivo Plc has a 4 week average price of 10.63p and a 12 week average price of 10.63p.
The 1 year high share price is 41p while the 1 year low share price is currently 10.63p.
There are currently 83,293,129 shares in issue and the average daily traded volume is 193,803 shares. The market capitalisation of Hvivo Plc is £9,786,942.66.
sunningdale1: Nothing happening IMO unfortunately. For those interested in alternative Pharma stocks (if you're not, no problem - this is a shameless plug) Open Orphan AIM:ORPH is one I’d recommend keeping an eye on - Share price has performed well over the last 6 months and it's no surprise - CEO Cathal Friel predicts 40% growth a year on podcast below with 2 million of his own money invested. hxxps:// Their health databank a standout for me and is progressing well. ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of Open Orphan’s Genomic Health Data platform and will speed up its launch. The companies CCO Maurice Treacy is holding a live webinar on Wednesday 30th October 2019 at 19:00 (UK time) for those interested: hxxps://
mam fach: At least it was a straightforward transfer of shares. Would have been devastating to share price if he just sold. Question is is this a wise move by Jupiter? Do they see value in HVO @ this price? Hard to call.
mam fach: Sneaky. Don't want share price to rise obviously. Hang on to your shares,
bernymadoff: The majority of people form opinions not based on company assets, financials and fundamentals but purely on the direction of the share price. They actually believe the Share Price is accurate/correct and true on a day-to-day basis regardless of the external factors that may affect it such as shorting, forced sellers etc. The biggest gains I have had on AIM by far have been my conviction buys that I've held for many months and sometimes well over a year. I have no doubt this will be right up there with the best of them.
tonyw99: I'm not saying either way but it doesn't matter when the options are exercised. They can be exercised (and then held) at any point for 8p and sold whenever she wants / needs cash. They wouldn't have "been allowed / advised" to cash them in at 160p - 210p because of the message it would give to the market - we're cashing out because we don't see any more upside. They could well be lining up a big payday however.....I'm not sure why the share price would spike on the back of it. If they sell as expected then they'll need the cash to run the service business. So unless they are going to return it to shareholders, that could be the only big gain. At which point, max capacity on revenue is c. £40m and a 10% return on ebitda would give off £4m. It wouldn't warrant a share price of more then £1 on 20 times PE
discojames: a1samu if youre going to deramp at least put ome effort in to it. "The share price will continue to collapse on lack of news", thats a blatant false premise as the share price hasnt collapsed and in fact has barely moved in over 2 months.
a1samu: The Directors have nothing concrete to report in the form of hard facts. There will be a lot of hot air of the future and potential and likely deals with unnamed parties, which will evaporate and the share price will continue to collapse on lack of news. They already released an RNS to say that news is imminent and we are still waiting. If there would be substantial news, like 10x bag value increase, they would not be able to hold it for the interim publication. Any substantial news they would be duty bound by the stock exchange rules to release immediately. As is, expect mediocre rubbish news tomorrow and further share price weakness, after perhaps a bounce, if lucky!
discojames: I disagree, Berny. Any test, with any sample size has the possibility to be flawed. Getting parallel results from an independent body is actually important to verify them and the next step up in the share price. Every party involved (us included) will be very happy to hear that a third party has backed up the incredible results so far, and I can see it having a large affect on the share price. Any major in talks with HVO over Flu-V will be waiting on this verification, why would they sign a deal now when they are so close to reading the NIH findings, unless such a deal included a get-out clauses if NIH results don't back up those of HVO's. It will then just be a question of when rather than if a deal will be signed to move Flu-V to the next stage. I would prefer a takeover or a sale of the rights over a joint venture (I think HVO are targetting the latter), but any of these options work for us obviously, in terms of the share price
applegarthlse: Not the first time shorters have gone after Neil Woodford? Read this article......Woodford slates Kerrisdale for shorting ProthenaFeature29 JAN 2018Neil Woodford hasn't held back in his criticism of the US hedge fund, Kerrisdale Capital, which recently moved to short one of his fund's top holdings, Prothena (PRTA.O).COMMENTWoodford Ingrid SmithIrish biotech company Prothena forms a relatively significant chunk of the Woodford Patient Capital Trust (WPCT).In November 2017 Kerrisdale published a less than positive 29-page report on Prothena, explaining why it had chosen to short the company's shares to inevitably profit from a fall in the share price, which saw a fall of nearly 28 per cent in Dollar terms on the Nasdaq.SPONSORED CONTENT Kubernetes on Windows – are we crazy?Kubernetes on Windows – are we crazy?By G-ResearchThe drop in Prothena's share price has cost it its top spot in the Patient Capital portfolio. From being the biggest holding at over 16 per cent of assets in October, it dropped to number two at 9.2 per cent by December, behind Oxford Nanopore, an unlisted university seeking to revolutionise DNA analysis.In its report, Kerrisdale argued that trials on Prothena's main drug under development – an antibody used to treat a rare disease called amyloidosis – is likely to fail and predicted Prothena will be 'the next big biotech blowup'.Woodford for his part said he is confident that Prothena, whose shares have rallied 20 per cent since the beginning of the New Year, will publish successful trial results in the second quarter, and forecasts there will be good news from other investments.'The next 6-12 months should see some important inflexion points, Woodford said. He added, "We are very confident about the portfolio", and said many companies in the Woodford Patient Capital Trust are "on the cusp" of a breakthrough.Some market watchers see Kerrisdale's comments as just another example of the long running feud between the hedge fund's founder, Sahm Adrangi, and Woodford.It was less than three years ago that Kerrisdale forecast shares in Allied Minds – a technology venture capitalist and another of the fund manager's long-term holdings – would tumble, describing many of its investments as 'duds'.Woodford has said Kerrisdale's raison d'etre is to frighten the market at a time when the market welcomes being frightened."It doesn't matter if what they said about Allied Minds and Prothena is totally inaccurate and unsubstantiated," Woodford told investors recently at a Winterflood Securities event in London.The star fund manager also argues that the financial press has a lot to answer for, by giving Kerrisdale "the oxygen of publicity" in order to achieve the self-fulfilled prophecy of a share price fall.The last year for Neil Woodford could be viewed as his very own annus horribilis, with all three of his funds having experienced a downturn in performance as key holdings have struggled – including the Woodford Equity Income fund which also invests in Prothena.And Woodford Patient Capital, which is an investment trust focused on early stage healthcare and technology companies, has certainly fared the worst.Since its inception in 2015 the fund's shares have fallen over 17 per cent to 83.4p, having lost 7 per cent of their value in 2017 and 9.75 per cent in 2016. This contrasts to August 2015, when they they were reported to show a 15 per cent premium over net asset value (NAV), but now trade at an 8.7 per cent discount to NAV.However, falls in the value of the underlying portfolio of 81 companies have been smaller, and the trust has still been able to report successes amongst it portfolio holdings – mostly notably from online estate agent Purplebricks(PURP), whose shares significantly jumped 194 per cent in 2017, according to Woodford Investment Management.
bernymadoff: IP are selling a few into a rising share price. That sale was made on Tuesday. We know that at the same time they've been selling Woodford has been buying. Actually Woodford is buying much more aggressively than they have been selling. Hence the share price has continued to rise. The rising share price tells us all we need to know which way the balance is tilted here
Hvivo share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191211 14:07:53